Table 3.
COVID-19 presentation of COVID-19-positive cancer patients.
| Total (n = 306) | WHO COVID grade | |||||
|---|---|---|---|---|---|---|
| Mild/moderate (n = 218) | Severe (n = 88) | |||||
| n | % | n | % | n | % | |
| Symptoms | ||||||
| Cough | 143 | 46.70 | 91 | 41.70 | 52 | 59.10 |
| Fever | 158 | 51.60 | 98 | 45.00 | 60 | 68.20 |
| Dyspnoea | 121 | 39.50 | 63 | 28.90 | 58 | 65.90 |
| Gastrointestinal symptoms | 45 | 14.70 | 26 | 11.90 | 19 | 21.60 |
| Time between first symptom and diagnosis | ||||||
| <7 days | 173 | 56.50 | 113 | 51.80 | 60 | 68.20 |
| 7–14 days | 53 | 17.30 | 35 | 16.10 | 18 | 20.50 |
| >14 days | 21 | 9.60 | 7 | 8.00 | 28 | 9.20 |
| Missing | 52 | 17.00 | 49 | 22.50 | 3 | 3.40 |
| Care setting | ||||||
| Outpatient | 68 | 22.20 | 67 | 30.70 | 1 | 1.10 |
| Inpatient | 210 | 68.60 | 150 | 68.80 | 60 | 68.20 |
| ITU | 27 | 8.80 | 0 | 0.00 | 27 | 30.70 |
| Missing | 1 | 0.30 | 1 | 0.50 | 0 | 0.00 |
| Laboratory values* | ||||||
| Ferritin (μg/L) | ||||||
| T1 (80–793) | 40 | 13.10 | 32 | 14.70 | 8 | 9.10 |
| T2 (891–1442) | 40 | 13.10 | 28 | 12.80 | 12 | 13.60 |
| T3 (1596–5958) | 39 | 12.70 | 17 | 7.80 | 22 | 25.00 |
| Missing | 187 | 61.10 | 141 | 64.70 | 46 | 52.30 |
| CRP (mg/L) | ||||||
| T1 (3–41) | 86 | 28.10 | 75 | 34.40 | 11 | 12.50 |
| T2 (42–117) | 81 | 26.50 | 52 | 23.90 | 29 | 33.00 |
| T3 (126–508) | 83 | 27.10 | 36 | 16.50 | 47 | 53.40 |
| Missing | 56 | 18.30 | 55 | 25.20 | 1 | 1.10 |
| Lymphocytes (×109) | ||||||
| ≤0.5 | 87 | 28.40 | 51 | 23.40 | 36 | 40.90 |
| 0.6–0.8 | 70 | 22.90 | 47 | 21.60 | 23 | 26.10 |
| 0.9–1.2 | 51 | 16.70 | 40 | 18.30 | 11 | 12.50 |
| >1.2 | 63 | 20.60 | 46 | 21.10 | 17 | 19.30 |
| Missing | 35 | 11.40 | 34 | 15.60 | 1 | 1.10 |
| Albumin (g/L) | ||||||
| T1 (20–32) | 84 | 27.50 | 41 | 18.80 | 43 | 48.90 |
| T2 (33–38) | 98 | 32.00 | 65 | 29.80 | 33 | 37.50 |
| T3 (39–57) | 68 | 22.20 | 62 | 28.40 | 6 | 6.80 |
| Missing | 56 | 18.30 | 50 | 22.90 | 6 | 6.80 |
aDistribution shown in tertiles (T).